Robert E. Waltermire - Feb 28, 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Senior VP, Chief Pharma Dev.
Signature
/s/ Brian J. Lynch
Stock symbol
MDGL
Transactions as of
Feb 28, 2023
Transactions value $
-$1,853,238
Form type
4
Date filed
3/2/2023, 03:30 PM
Previous filing
Jan 18, 2023
Next filing
Dec 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $440K +5K +88.23% $87.92 10.7K Feb 28, 2023 Direct
transaction MDGL Common Stock Sale -$244K -900 -8.44% $271.03 9.77K Feb 28, 2023 Direct F2
transaction MDGL Common Stock Sale -$1.12M -4.1K -41.98% $272.30 5.67K Feb 28, 2023 Direct F3
transaction MDGL Common Stock Options Exercise $440K +5K +88.23% $87.92 10.7K Mar 1, 2023 Direct
transaction MDGL Common Stock Sale -$527K -1.93K -18.07% $273.44 8.74K Mar 1, 2023 Direct F4
transaction MDGL Common Stock Sale -$459K -1.67K -19.13% $274.57 7.07K Mar 1, 2023 Direct F5
transaction MDGL Common Stock Sale -$358K -1.3K -18.4% $275.53 5.77K Mar 1, 2023 Direct F6
transaction MDGL Common Stock Sale -$27.6K -100 -1.73% $276.19 5.67K Mar 1, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -5K -14.29% $0.00 30K Feb 28, 2023 Common Stock 5K $87.92 Direct F1
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -5K -16.67% $0.00 25K Mar 1, 2023 Common Stock 5K $87.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All shares issued pursuant to the exercise of the options reported herein represent 10,000 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.58 to $271.47, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.82 to $272.77, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.00 to $274.00, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.06 to $274.99, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.18 to $276.18, inclusive.

Remarks:

As attorney-in-fact for Reporting Person